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Abstract
This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the ﬁeld
in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of
invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials
on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected,
and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad
answering system. After the initial conference, the viewpoint document has been reviewed and edited to include new insights and devel-
opments since the initial meeting. For many situations, consensus on treatment could not be reached, and the responses indicate that
treatment is likely to be modiﬁed on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azole
antifungals, and the presence of potentially antifungal drug-resistant Candida species.
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Introduction
Invasive candidiasis, mostly candidaemia, is associated with a
high global mortality rate, ranging from 36% to 63% in differ-
ent patient groups [1–4], and represents a signiﬁcant burden
on the public health system in terms of patient management
and healthcare costs. In a prospective hospital-based popula-
tion study in seven European countries, rates of candidaemia
ranging from 0.20 to 0.38 per 1000 hospital admissions were
reported [3]. Approximately half of all Candida infections
now occur in intensive-care units (ICUs) [5,6]. An increase
in the incidence of candidaemia between 1999 and 2006 was
reported from several countries [7–9].
Although Candida albicans is still the leading cause of inva-
sive candidiasis in most clinical settings [3,8], there has been a
signiﬁcant pathogen shift towards other Candida species over
the past few years in some patient groups [3,7,10]. The
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changing epidemiology has been partly attributed to selection
of less sensitive Candida strains, owing to the widespread use
of ﬂuconazole as a prophylactic and therapeutic agent [11,12].
Over the years, a variety of new antifungal drugs have
been introduced. Although these developments mean that
clinicians now have more choices when selecting an antifun-
gal drug, the most effective treatment regimens for invasive
candidiasis are uncertain. In 1997, Edwards et al. [13] pub-
lished the results of an international conference to develop a
consensus on the management of severe Candida infections.
In an attempt to review the treatment strategies for invasive
candidiasis with a global European perspective, we held a
similar meeting to that of Edwards et al. [13], based on the
views and current practices of a panel of European experts
in clinical mycology. As in the previous study, where opinions
differed between the experts, the aim was to present the full
diversity of opinion from all participants.
Participants and Consensus Methods
The panel consisted of 26 experts (infectious diseases physi-
cians, medical microbiologists, mycologists, haematologists,
and intensivists) from 13 European countries. Each was
invited because of their expertise in studies on candidiasis
and the management of patients with Candida infections.
A list of questions regarding treatment strategies for
severe Candida infections in adults was developed by two of
us (B.J.K. and P.E.V.). As in the previous consensus meeting
[13], questions were reviewed and edited during the meet-
ing, and the wording of possible answers to the questions
was reviewed, extensively discussed, and revised. Subse-
quently, the issues were discussed and the answers to the
questions were voted on anonymously, by the use of elec-
tronic keypad devices. The moderators of the meeting (B.J.K.
and P.E.V.) did not vote. The manuscript generated from the
meeting results was distributed, reviewed, edited, and dis-
cussed by all participants to include new insights and devel-
opments since the initial consensus meeting. This report
discusses the full spectrum of responses to each question
and treatment preferences.
Results
Initial management of candidaemia
Should all patients with a positive blood culture for Candida be
treated?
Background: Nosocomial candidaemia is associated with
high levels of mortality in critically ill patients [2], especially if
antifungal therapy is delayed [14,15]. However, up to 85% of
patients with candidaemia do not receive appropriate antifun-
gal therapy for 24 h or more until blood culture results are
known [14]. Whereas transient, self-limited candidaemia may
resolve without antifungal therapy, patients with candidaemia
who will recover without antifungal therapy are currently
impossible to identify.
Responses: All panellists indicated that they would treat all
patients with a Candida-positive blood culture, irrespective of
clinical status and underlying risk factors. Reluctance to do so
among some clinicians is likely to be attributable to confusion
about the signiﬁcance of positive blood cultures from samples
taken via a central intravascular catheter. In a retrospective
review of 155 episodes of vascular catheter-related candida-
emia in cancer patients, the frequency of autopsy-proven
candidiasis was similar irrespective of whether blood was
obtained via a central catheter or from a peripheral site [16].
A recent series of 370 episodes of candidaemia reported by
Kullberg et al. [17] suggested that positive blood cultures for
Candida from samples obtained via an indwelling intravascular
line should never be disregarded in a symptomatic patient
with concomitant signs of infection. These studies demon-
strate the need to treat all patients with positive blood
cultures irrespective of the site of blood collection.
What determines the choice of initial antifungal therapy in a
patient with candidaemia before the species has been deter-
mined?
Background: It is difﬁcult to know which antifungal drug is
the most effective to use before the yeast species and suscepti-
bility have been determined. The severity of illness (ICU
admission or haemodynamic instability) is felt by most to be a
major determinant in selecting an appropriate antifungal agent,
in addition to the local epidemiology of Candida. A recent
French multicentre ICU cohort study reported that 17% of
Candida isolates were less susceptible to ﬂuconazole [18].
However, no clinical factor to guide the choice of therapy was
apparent [19]. We assumed previous exposure to azoles
(either as prophylaxis or as treatment) to be a major risk
factor for colonization with less susceptible Candida species,
and thus considered ‘azole-naı¨ve’ patients to be separate from
azole-exposed patients when selecting initial therapy.
Sample case. An adult recently admitted to the ward with uncom-
plicated sepsis, is azole-naı¨ve, has normal liver and renal function,
and has candidaemia. What would be the initial choice of
therapy?
Background: In most European countries, six antifungal
drugs have been approved for candidaemia: ﬂuconazole,
amphotericin B desoxycholate (d-AmB), voriconazole,
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anidulafungin, caspofungin, and micafungin. Recent clinical
trials have demonstrated non-inferiority or superiority of the
newer antifungal agents as compared with conventional
d-AmB or ﬂuconazole. Caspofungin was shown to be
non-inferior to d-AmB in patients with invasive candidiasis
(response rates of 73% vs. 62% at end of intravenous study
drug administration (end of treatment (EOT)), p 0.09)
[20,21], whereas voriconazole was non-inferior to a regimen
of d-AmB followed after 3–7 days by ﬂuconazole in patients
with candidaemia (response rates of 70% vs. 74% at EOT,
p 0.42) [5]. Both caspofungin and voriconazole were better
tolerated than d-AmB, and were associated with fewer drug-
related side effects. Three further phase III clinical trials
showed that anidulafungin and micafungin are also effective
antifungal drugs for the treatment of invasive candidiasis
[22–24]. Anidulafungin was superior to ﬂuconazole in 261
patients with candidaemia or invasive candidiasis, with global
response rates of 75.6% vs. 60.2% at EOT (p 0.01) [22], and
superior efﬁcacy in infections caused by C. albicans (81.1% vs.
62.3%) and non-albicans species (71.1% vs. 60.0%), with the
exception of Candida parapsilosis [22]. Intravenous micafungin
(100 mg daily) was non-inferior to liposomal amphotericin B
(LAmB) in 531 patients with invasive candidiasis or candida-
emia, with successful outcomes in 74% and 70% at EOT, but
micafungin was better tolerated than LAmB [23]. In a three-
armed study, intravenous micafungin (150 or 100 mg daily)
was non-inferior to caspofungin (71% vs. 74% vs. 71% overall
success, not signiﬁcant (NS)) [24]. A recent randomized study
reported no signiﬁcant beneﬁt of caspofungin at 150 mg daily
as compared with 50 mg daily in patients with invasive candi-
diasis (80% vs. 72% overall success at EOT, NS) [25].
A comparative trial of intravenous itraconazole and ﬂuco-
nazole in 193 patients with candidaemia has reported similar
success rates (67% vs. 69% overall success at EOT, NS), but
this study was never published in full [26].
Response: On the basis of published clinical trial data,
ﬂuconazole (16 panellists) or an echinocandin (ﬁve panellists)
were the most likely regimens to be selected for primary
therapy of candidaemia in a stable, azole-naı¨ve, mildly to
moderately ill patient with uncomplicated sepsis (Fig. 1a).
In a recent comparative trial, anidulafungin was superior
to ﬂuconazole both in C. albicans and non-albicans Candida
infections [22], favouring the use of echinocandins in severely
ill patients. However, most panellists found that there were
currently insufﬁcient data to make an informed judgement
on the potential superiority of anidulafungin or other echino-
candins over ﬂuconazole in mildly to moderately ill, stable,
azole-naı¨ve patients.
Only two panellists would use d-AmB as primary therapy.
None of the panellists felt that itraconazole has a role in the
treatment of invasive candidiasis, because of its potential for
unfavourable drug interactions, drug-related adverse events,
and the lack of published clinical trial data [27].
Although voriconazole proved to be equally effective as d-
AmB [5], in clinical practice this drug was preferred as oral
step-down therapy or for use in special cases where other
antifungal agents were contraindicated.
It is of note that positive blood cultures are usually reported
as positive for ‘yeasts’. Although the most likely identity will be
Candida species, the experts acknowledged that other yeasts,
such as Cryptococcus and Trichosporon species, cannot be
discounted, as they are not susceptible to echinocandins.
An adult patient with uncomplicated 
sepsis, and a blood culture positive 
for yeast, with normal renal and 
hepatic function 
An adult patient with uncomplicated 
sepsis, and a blood culture positive 
for yeast, with normal renal and 
hepatic function, who had received 
fluconazole previously during this 
admission  
(a) 
(b) 
FIG. 1. Responses to the questions on initial treatment of candidaemic patients: (a) uncomplicated; (b) received ﬂuconazole previously during
this admission.
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Is amphotericin B applicable in the treatment of adult patients
with invasive candidiasis?
Background: Intravenous d-AmB has remained the refer-
ence standard for treating invasive fungal infections since its
introduction in 1959, despite its acute infusion-related toxic-
ity and nephrotoxicity. In comparative trials, the limited suc-
cess rate of d-AmB was shown to be primarily attributable
to its toxicity, leading to premature treatment discontinua-
tions in many patients [5,20,28,29]. This was true even if d-
AmB was given only for a median of 4 days, before stepping
down to ﬂuconazole [5].
Responses: The majority (14/22) of the panel felt that d-
AmB no longer has a role in the therapy of invasive candidia-
sis, owing to the serious side effects associated with this
drug. However, for second-line treatment of candidaemia, a
lipid-based formulation of amphotericin B could be consid-
ered, despite the lack of comparative studies, with most
favouring LamB, in view of the availability of recent data [23].
Which antifungal agent should be used to treat an adult, azole-
naı¨ve patient with candidaemia during a prolonged hospital stay?
Background: Most cases of nosocomial candidiasis are
endogenous in origin and emanate from the patient’s own gas-
trointestinal ﬂora, although nosocomial transmission has been
described [30]. Prolonged hospitalization is associated with a
shift towards Candida species other than C. albicans, particularly
after ﬂuconazole prophylaxis [11,12]. Recent European studies
have demonstrated increasing rates of decreased susceptibility
to ﬂuconazole in some but not all settings [7,18,31].
Responses: Two-thirds of the panel appeared to have no
concerns about the increased risk of ﬂuconazole resistance
during a prolonged hospital stay, provided that patients had
not been exposed to any azole therapy, and would use this
drug as ﬁrst-line therapy, as for a stable, hospital-naı¨ve
patient. One-third of the panel, however, preferred to use a
broad-spectrum drug until species and susceptibility proﬁles
have been established.
Which antifungal agent should be used to treat an adult patient
with candidaemia who had received ﬂuconazole previously during
this admission?
Responses: Whereas there was no overall consensus on
antifungal treatment for hospital-naı¨ve or hospital-experi-
enced patients, all panellists agreed that prior exposure to
ﬂuconazole would inﬂuence their choice of antifungal drug to
cover possible ﬂuconazole resistance; 21 would use an echi-
nocandin, and only two would use d-AmB (Fig. 1b).
Which antifungal agent should be used to treat an azole-naı¨ve,
non-neutropenic, adult ICU patient with candidaemia?
Background: Medical and surgical ICUs have seen a substan-
tial increase in the incidence of invasive candidiasis in recent
years [4]. The emergence of Candida glabrata as a major
pathogen among these patients [10] has been attributed to
the increased use of ﬂuconazole prophylaxis in ICU patients.
Responses: If an azole-naı¨ve patient had uncomplicated sep-
sis and normal renal and hepatic function and was in an ICU,
13 of the 23 panellists indicated that they would still use ﬂuco-
nazole. However, most panellists acknowledged that the study
on anidulafungin vs. ﬂuconazole has suggested the superiority
of echinocandins, even in less severely ill patients [22].
The presence of severe sepsis caused panellists to modify
their approach to treatment. The majority (20) of the panel
indicated that they would use an echinocandin rather than
ﬂuconazole (Fig. 2a); only two would use ﬂuconazole in this
setting. Although combined therapy with d-AmB plus ﬂuco-
nazole was more effective than high-dose ﬂuconazole (800 mg
daily) plus placebo at clearing Candida from the bloodstream
of non-neutropenic adult patients with candidaemia [29],
there was no enthusiasm for this combined regimen among
the panel of experts, in view of the d-AmB-associated toxicity.
Choice of echinocandin: Currently, anidulafungin, caspo-
fungin and micafungin are available in most European coun-
tries. The panellists noted very little difference in overall
efﬁcacy between these agents during the discussion at the
conference, and this view was conﬁrmed during subsequent
discussions and review of this manuscript. More recently, the
EMA, but not the FDA, has issued a caution that micafungin
should only be used if other antifungals are not appropriate,
as rat experiments (but not data from humans) suggested a
potential risk for the development of liver tumours (http://
www.ema.europa.eu/humandocs/Humans/EPAR/mycamine).
Which antifungal drug should be used to treat an adult neutrope-
nic haematology patient with candidaemia, who had not received
azole prophylaxis?
Background: LAmB, voriconazole and caspofungin have
been investigated for the empirical treatment of haematologi-
cal patients with unexplained fever during prolonged neutro-
penia [32–34]. C. glabrata and Candida krusei are more
prevalent in haematology patients [3], and infection with
these species may be refractory to ﬂuconazole treatment.
However, no comparative studies have been speciﬁcally
performed in neutropenic patients with culture-proven
candidaemia, and published studies have included very few
neutropenic cases [20,22–24], precluding any conclusions on
the efﬁcacy of speciﬁc antifungal regimens for candidaemia in
these patients.
Responses: If a patient had uncomplicated sepsis and nor-
mal renal and hepatic function, 13 panellists indicated that
4 Clinical Microbiology and Infection, Volume 17 Supplement 5, September 2011 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17 (Suppl. 5), 1–12
they would use an echinocandin, nine would use ﬂuconazole,
and one would use voriconazole (Fig. 2b). It is of note that
voriconazole and anidulafungin are not currently licensed for
this indication in Europe.
Follow-on treatment or treatment in speciﬁc cases
What would be the choice of antifungal drug for an uncomplicated
adult patient with ﬂuconazole-susceptible C. albicans candidaemia?
Background: Antifungal susceptibility testing methods
include those of the CLSI and the European Committee on
Antimicrobial Susceptibility Testing (EUCAST-AFST), as well
as the commercial Etest. Not only do the CLSI and EU-
CAST-AFST differ in their breakpoints for ﬂuconazole and
voriconazole, but the EUCAST-AFST states that C. glabrata
and C. krusei are not considered to be good targets for
ﬂuconazole, and there is as yet insufﬁcient evidence to estab-
lish reliable breakpoints for voriconazole for those species
[35,36]. In addition, the CLSI adopts the category of suscep-
tible-dose-dependent to allow for dosage increases. Echino-
candin resistance of Candida has been increasingly reported
over the last few years, and is associated with various hot
spot mutations in the FKS target gene [37–39]. In general, a
median of 3 weeks of exposure has preceded the develop-
ment of resistance, which has not been reported for echino-
candin-naı¨ve patients [38,39]. The isolates are characterized
by elevated MICs for all available echinocandin agents, cross-
resistance in animal infection models, and breakthrough
infections in patients. Consequently, alternative drug classes
are recommended to treat those cases [39–41].
Responses: All panellists favour ﬂuconazole (400 mg daily)
in a stable, uncomplicated patient once they know that the
C. albicans is susceptible. Even in a patient who was respond-
ing to an echinocandin, all 23 panellists indicated that they
would switch to ﬂuconazole as long as the patient had
become stable and the isolate was sensitive, in view of the
lower costs and oral availability of ﬂuconazole. These results
underscore that all panellists recommended an active step-
down approach to streamline antifungal therapy as soon as
the patient had stabilized and the species and susceptibility
had become available. As mentioned above, panellists
acknowledged that the study on anidulafungin vs. ﬂuconazole
may shed new light on the comparative efﬁcacies of ﬂuconaz-
ole and echinocandins in the future, even in haemodynamical-
ly stable patients [22].
What would be the choice of antifungal drug for an uncompli-
cated adult with C. glabrata candidaemia?
Responses: Even if the C. glabrata isolate was demon-
strated to be ﬂuconazole-susceptible in vitro, most panellists
were concerned about using ﬂuconazole for a C. glabrata
infection. Over 50% of panellists favoured using an echino-
candin, whereas ﬁve indicated that they would increase the
ﬂuconazole dose to 800 mg daily. Only ﬁve panellists indi-
cated that they would be prepared to use ﬂuconazole at a
dose of 400 mg daily (Fig. 3a).
However, if the patient had been started on ﬂuconazole
(400 mg daily) and was stabilized and doing well at the time
when species and susceptibility became known, seven of 24
panellists were inclined to continue treatment, but the
majority would either increase the dose to 800 mg daily or
higher or switch to another agent. Seven of the panellists
would prefer to switch to an echinocandin, and one favoured
voriconazole, regardless of the clinical status of the patient. If
ﬂuconazole was continued, the panellists agreed that the
An adult ICU patient with 
severe sepsis, and a blood 
culture positive for yeast 
An adult neutropenic 
hematology patient with 
uncomplicated sepsis without 
azole prophylaxis, and a blood 
culture positive for yeast 
(a) 
(b) 
FIG. 2. Responses to the questions on initial treatment of candidaemic patients: (a) in the intensive-care unit (ICU) with severe sepsis, unstable
or moderately to severely ill; (b) neutropenic haematology patient without azole prophylaxis.
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patient’s condition should be monitored closely for any signs
of clinical deterioration, which may initiate a switch to an
alternate antifungal.
What would be the choice of antifungal drug for an uncompli-
cated adult patient with C. krusei candidaemia?
Responses: As C. krusei is inherently resistant to ﬂuconaz-
ole, most of the panellists (22/23) indicated that they would
use an echinocandin, and one would use voriconazole (Fig. 3b).
What would be the choice of antifungal drug for a responding
adult patient started on caspofungin who is infected with C. par-
apsilosis?
Background: The correlation between MICs and in vivo
response is less clear for the echinocandins than for ﬂuco-
nazole, and interpretive breakpoints have been more difﬁcult
to establish. Echinocandin drugs consistently show higher
MICs for C. parapsilosis than for other Candida species
[40,42], and there are reports of increased clinical failure and
persistence of infection with this species [20,22,25,43–45].
Responses: Interestingly, most of the panel felt that this
issue should be taken at least as seriously as C. glabrata
ﬂuconazole resistance; only ﬁve panellists indicated that they
would continue with an echinocandin, whereas 17 of 22
would switch to another class of antifungal drug, even if the
susceptibility of the strain was within the range usually con-
sidered to be susceptible in vitro (e.g. MIC of 1 mg/L). If the
patient was not responding to an echinocandin at all, all 23
panellists indicated that they would switch the class of anti-
fungal drug and use an azole compound.
What are the indications for primary combined therapy with two
antifungal agents in invasive candidiasis?
Background: Antifungal combination therapy has been
advocated in a few speciﬁc areas, e.g. Candida endocarditis.
Combined medical and surgical approaches, including surgical
removal of infected heart valves or implanted devices and
debridement of infected perivalvular tissue, are essential to
the successful management of Candida endocarditis. Combined
antifungal therapy regimens including ﬂucytosine have
been recommended for Candida endocarditis, endophthalmitis,
and central nervous system infections, as ﬂucytosine pene-
trates well into all body tissues, including cerebrospinal ﬂuid,
and has documented synergistic activity with amphotericin B
[46].
Responses: The majority of the panellists agreed that
there are currently no proven indications for primary combi-
nation therapy in adult patients with invasive candidiasis
(Fig. 3c). However, for Candida endocarditis, several panel-
lists indicated that they would use combination therapy with
either a lipid-associated amphotericin B plus ﬂucytosine (ﬁve
votes) or an echinocandin plus ﬂucytosine (eight votes).
An adult patient with a 
fluconazole-susceptible 
C. glabrata candidaemia 
An adult patient with a 
C. krusei candidaemia 
An adult patient with a  
C. parapsilosis candidaemia, 
clinically responding to initial 
therapy with an echinocandin 
(a) 
(b) 
(c) 
FIG. 3. Responses to the questions on treatment of candidaemic patients (a) infected with ﬂuconazole-susceptible Candida glabrata; (b) infected
with Candida krusei; or (c) infected with Candida parapsilosis and clinically responding to initial therapy with an echinocandin.
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For a patient with a cerebral Candida infection, many
would use ﬂuconazole (eight votes) or voriconazole (ﬁve
votes), whereas ten favoured combined therapy, mostly lipid-
associated amphotericin B + ﬂucytosine. The choice of voric-
onazole was mainly based on extrapolation from the many
case reports in the literature on the successful management
of cerebral aspergillosis with voriconazole [47]. None of the
panellists would recommend echinocandin monotherapy for
cerebral candidiasis; penetration of this drug into the central
nervous system was thought to be insufﬁcient, and most pan-
ellists felt that there was a lack of data to support this indi-
cation.
On the basis of published data, what is the role of efungumab?
Background: Efungumab (trade name: Mycograb) is a
human recombinant monoclonal antibody against heat shock
protein 90 with antifungal activity in vitro. It is not currently
approved anywhere in the world, but it was under develop-
ment at the time of this conference, and its potential role
was discussed. In a randomized comparison of lipid-associ-
ated amphotericin B plus efungumab vs. lipid-associated
amphotericin B plus placebo in 139 patients with candidiasis,
signiﬁcantly better outcome was reported for efungumab
plus amphotericin B than for amphotericin B plus placebo
(complete overall response by day 10, 84% vs. 48%, respec-
tively; p <0.001). No serious side effects were reported in
the publication [48].
Responses: Although the majority of the panellists felt that
immunotherapy was potentially interesting, the only pub-
lished trial was unconvincing, and concerns were expressed
about some aspects of the study design and report. The pan-
ellists’ consensus was that the study raised many unanswered
questions, including patient selection, assessment of end-
points, blinding, independent data review, adverse effects,
and even potentially increased mortality in the efungumab
group [48,49]. After in-depth discussion, the majority of pan-
ellists indicated that they would not consider using ef-
ungumab for the time being, as there are insufﬁcient data
available to support its use.
Follow-up and management of patients
Would you obtain follow-up cultures after the start of therapy in
patients with candidaemia?
Background: The Practice Guidelines for the Treatment of
Candidiasis published by the Infectious Diseases Society of
America (IDSA) [50] recommend that treatment of candida-
emia be continued for 2 weeks after the last positive blood
culture has been obtained and resolution of signs and symp-
toms of infection has occurred. However, these cultures are
infrequently obtained, and there are currently no recommen-
dations to obtain follow-up cultures in any ofﬁcial guidelines.
In clinical practice, physicians seldom seem to follow the
guideline to base duration of treatment on the course of
blood culture positivity [51].
Responses: All of the panellists indicated that they would
perform follow-up cultures after the start of therapy,
although six indicated that they would not do this for every
single patient. This is in line with the treatment guidelines
mentioned above, which relate duration of treatment to the
last positive blood culture. Although there was no formal
vote on the subject of treatment duration in candidaemia
and invasive candidiasis, it was agreed that clinicians should
follow the guidelines proposed by the IDSA [50].
Should ophthalmoscopy be performed on patients with candida-
emia?
Background: The incidence of Candida endophthalmitis or
chorioretinitis in patients with candidaemia has been
reported to range from 5% to 78% [52,53]. In a large series
of 370 non-neutropenic candidaemic patients who prospec-
tively underwent repeated ophthalmoscopy [5], 16% had
ocular involvement, and in 9.5% this was probably or deﬁ-
nitely caused by Candida. The IDSA treatment guidelines rec-
ommend that all patients with candidaemia should undergo
ophthalmoscopy, including a dilated retina examination [50].
Responses: Eighteen panellists indicated that it was impor-
tant to carry out ophthalmoscopy, whereas four thought that
ophthalmoscopy was not indicated, as the antifungal drugs
used to treat candidaemia would clear the ocular site as well;
however, the panel felt that this was less likely with the echi-
nocandins than with azole drugs. Ophthalmoscopy should
not be performed too early, as lesions may become visible
during therapy; it was agreed that ophthalmoscopy should be
carried out before antifungal treatment is stopped, to enable
a decision to prolong treatment if required.
Should intravenous catheters be removed if feasible?
Background: Indwelling intravenous catheters do not nec-
essarily represent the origin of candidaemia, but may act as a
reservoir of infection that may prolong candidaemia and lead
to metastatic foci of infection. Early removal of central
venous catheters from patients with bloodstream infection
has been considered to be essential to successful patient
management [54] and is currently recommended in the IDSA
guidelines for candidaemia [50]. Exchange of a catheter at
the original site over a guide wire was thought not to be
beneﬁcial [54]. A recent literature review found that only
one study revealed a deﬁnite beneﬁt of catheter removal in
neutropenic patients with candidaemia [55], and a large anal-
ysis was unable to demonstrate a beneﬁcial effect of early
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catheter removal in candidaemic patients treated with an
echinocandin or LAmB [56]. It has been recommended that
the beneﬁts of catheter removal should be weighed carefully
against the risks for each patient [57].
Responses: Despite the paucity of data on catheter man-
agement and proof of the perceived beneﬁts of catheter
removal, all panellists indicated that removal of intravascular
catheters should be considered in a patient with candida-
emia, and 20 of 22 indicated that these catheters should be
removed if feasible.
Panellists had differing views about the minimum required
time interval between central catheter removal and insertion
of a new catheter at a new body site, although most (16/23)
indicated that a new catheter could be inserted straight away
and that no delay was necessary. It is important that antifun-
gal therapy be started before catheter exchange, and, in the
presence of an antifungal in the bloodstream, most panellists
felt that subsequent bioﬁlm formation and colonization of
the new catheter would be prevented even if it was inserted
without a catheter-free interval.
Prophylaxis and empirical therapy in the ICU
Are there any ICU patients for whom prophylaxis is routinely indi-
cated?
Background: Patients in ICUs have a high risk of develop-
ing invasive candidiasis, which increases with the length of
ICU stay. Studies on prophylaxis with ﬂuconazole have
shown a reduction in the incidence of invasive Candida infec-
tions but not an improvement in survival in selected subsets
of high-risk ICU patients [58–60]. Antifungal prophylaxis
should be targeted at speciﬁc patients at high risk of devel-
oping candidiasis [61], and various selection rules have been
proposed to identify such patients [62].
Responses: Most panellists (18/21) felt that prophylaxis
was indicated for some ICU patients. All of the prophylaxis
trials to date have considered highly selected subsets of pop-
ulations, and none of the studies has addressed the general
ICU population. All experts felt that high-risk solid organ
transplantation (liver or kidney–pancreas) is the most impor-
tant factor requiring anti-Candida prophylaxis. Other risk fac-
tors that would make the panellists consider antifungal
prophylaxis included major abdominal surgery, new renal fail-
ure requiring haemodialysis/haemoﬁltration, total parenteral
nutrition, prolonged use of broad-spectrum antibiotics, and
prolonged ICU stay. As these factors are present in many
ICU patients, it was felt that they should not be considered
as indications for prophylaxis until a well-validated decision
rule is available, and that further studies are required to
identify speciﬁc high-risk groups so that antifungal prophy-
laxis can be targeted to those who will most beneﬁt from it.
Are there any subsets of ICU patients for whom empirical therapy
is indicated, and which risk factor would prompt intensivists to ini-
tiate empirical anti-Candida therapy?
Background: The IDSA guidelines state that empirical ther-
apy should be administered only to febrile patients with Can-
dida colonization (preferably at multiple sites) and multiple
other risk factors in the absence of any other demonstrable
cause of fever [50]. However, only about half of the ICU
patients with candidaemia are known to be colonized at the
time when the infection is diagnosed, mostly because they
acquire candidaemia early during their ICU stay [62]. A ran-
domized controlled trial of 800 mg/day ﬂuconazole vs. pla-
cebo showed no overall beneﬁt in 270 adult ICU patients
with fever despite administration of broad-spectrum antibiot-
ics [63]. Nevertheless, retrospective studies demonstrating a
strong correlation between delay in the start of antifungal
therapy and mortality in candidaemic patients [14,15] suggest
that early empirical therapy in patients at high risk of having
candidaemia may be beneﬁcial.
Responses: The large majority of panellists (22/24) agreed
that empirical therapy is indicated in some subsets of ICU
patients. In identifying those ICU patients with unexplained
sepsis or septic shock (not just unexplained fever) who may
beneﬁt from early empirical antifungal therapy while blood
culture results are pending, the panellists identiﬁed several
important risk factors: colonization at other body sites was
considered to be the most important risk factor (19
responses), and major abdominal surgery was also considered
to be important (12 responses), as were positive catheter tip
cultures (16 responses), although not justifying empirical
therapy if present as a single risk factor [64]. Prolonged ICU
stay, prolonged use of broad-spectrum antibiotics, the pres-
ence of a central line and haemodialysis/haemoﬁltration were
considered to be less important. These responses are in
agreement with a recent cohort study in Spain, which identi-
ﬁed similar risk factors [65,66]. Only 12 panellists indicated
that they carried out surveillance cultures for Candida in ICU
patients, and 14 did so in neutropenic patients, whereas the
others did not carry out surveillance cultures routinely.
Diagnosis of invasive candidiasis
What is the clinical utility of the b-D-glucan assay?
Background: The diagnosis of invasive candidiasis relies
essentially on the culture of blood and other specimens from
normally sterile body sites. Several tests to detect Candida
antigens or antibodies are now available commercially
(CandTec, Pastorex Candida, Platelia Candida Ag (BioRad,
Marnes-la-Coquette, France); Fungitec G-test (Seikagaku,
Tokyo, Japan); Fungitell (Associates of Cape Cod, East
Falmouth, MA, USA)). Tests for the detection of Candida
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mannan (Pastorex Candida; Platelia Candida Ag) and anti-
mannan antibodies have been explored in different patient
populations [67], but have shown variable sensitivity and
speciﬁcity in patient groups including surgical and ICU
patients [67–70]. Tests for the measurement of serum
(1 ﬁ 3)-b-D-glucan (Fungitec G-test; Fungitell) are not spe-
ciﬁc to Candida infection, as they detect b-D-glucan from
many fungal pathogens, including Aspergillus spp. and Fusarium
spp. [68,71]. However, detection of b-D-glucan may be a use-
ful adjunct for the diagnosis of candidiasis in addition to
other indicators of infection [66].
Responses: Only six panellists indicated that they would
use the b-D-glucan assay in selected patients, and 15 indi-
cated that there was insufﬁcient evidence from clinical stud-
ies to support the use of this assay routinely. Panellists felt
that the lack of a control ‘at-risk’ population in the above
studies precludes a deﬁnitive judgement on the predictive
value of the test in clinical practice, and there were concerns
about the high rate of positive results in patients with other
fungal infections.
Most panellists considered the incidence of candidaemia
to be too low to justify the expense of the b-D-glucan test.
They also felt that a negative mannan test result and a nega-
tive b-D-glucan test result may be more useful for exclusion
of a diagnosis of candidaemia than a positive result would be
for the initiation of therapy.
Summary
All panellists participating in this European consensus confer-
ence agreed on the need for early intervention in candida-
emia and the need to treat all patients with candidaemia.
Despite the conﬂicting data [56], there was also a consensus
that central intravenous lines should be changed wherever
possible, with most but not all panellists agreeing that a new
line can be inserted straight away. Overall, there was no
consensus on the most effective antifungal strategy, but there
was an obvious swing away from amphotericin B, because of
drug-related toxicity. Panellists strongly agreed that treat-
ment strategies need to be modiﬁed on an individual patient
basis, depending on local epidemiological data, degree of
immune compromise, history of recent azole exposure, and
severity of illness. Most panellists favoured an echinocandin
in moderately or severely ill patients with candidaemia, those
recently exposed to azole drugs, and those with C. glabrata
or C. krusei infection. Although anidulafungin was found to be
superior to ﬂuconazole in a recent comparative candidaemia
trial [22], most panellists felt that there were currently insuf-
ﬁcient data available to judge the potential superiority of ech-
inocandins over ﬂuconazole in mildly ill, stable, azole-naı¨ve
patients. Although most panellists agreed that there is cur-
rently no indication for primary combination therapy in can-
didaemia, a number of the panellists felt that combination
therapy was useful for cerebral Candida infections and endo-
carditis.
Although serological methods can provide an early diagno-
sis of infection before blood culture results are known, most
experts felt that these assays do not have sufﬁcient sensitiv-
ity or speciﬁcity to inﬂuence their clinical decision-making.
Most panellists agreed that antifungal prophylaxis in ICU
patients is indicated in some but not all patients. As in previ-
ous published studies [61,62,65], panellists felt that further
work was necessary to identify precisely which subsets of
patients would beneﬁt the most from antifungal prophylaxis.
There was also agreement that empirical therapy would be
useful in some subsets of ICU patients with unexplained sep-
sis. Candida-positive catheter tips, colonization at multiple
body sites and major abdominal surgery were considered to
be the principal risk factors for candidaemia justifying empiri-
cal therapy in septic patients.
The data from this European expert consensus document
show that the introduction of a number of new antifungal
drugs has served to facilitate a more tailor-made approach
to antifungal therapy. Further clinical trials are required to
compare different antifungal treatment regimens in speciﬁc
patient populations, in order to determine the most effective
treatment strategy for deﬁned subsets of patients. Until
these have been carried out and data are available to
demonstrate clinical superiority of one antifungal drug over
another, antifungal treatment needs to be modiﬁed on
an individual patient basis and should be guided by local
experience.
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